Genentech Pays US$120 M Upfront for UCB’s Tau-targeting Antibody UCB0107
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 8 (Table of Contents)
Published: 4 Aug-2020
DOI: 10.3833/pdr.v2020.i8.2554 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Broadening its presence in the CNS space, Roche’s Genentech has licensed the worldwide rights to develop and commercialise UCB’s tau-targeting antibody UCB0107 for the treatment of Alzheimer’s disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS